

ASIA’s LEADING ADC R&D & MANUFACTURING CONFERENCE

Key Themes & Topics
The Concept
Asia’s Leading ADC R&D & Manufacturing Conference – Uniting Asia Leaders in Antibody- Drug Conjugates Market
Asia has rapidly emerged as the most dynamic and promising region in the global Antibody-Drug Conjugate (ADC) landscape. With a surge in biotech innovation, multibillion-dollar investments, and strategic partnerships centered around Asian companies, the region is no longer just a rising player—it is setting the pace for the future of ADC development.
From pioneering novel targets to exploring next-generation linker and payload technologies, Asian innovators are reshaping the ADC ecosystem. As clinical programs originating from the region progress into late-stage development, the global industry is closely watching for breakthrough clinical validation that could redefine the therapeutic potential of ADCs.
The ADC Asia Congress 2026 returns to Singapore—bigger, broader, and more influential than ever—as the leading platform for advancing the science, strategy, and success of ADCs in Asia-Pacific. Designed as the most comprehensive ADC conference dedicated to the Asian community, the 2026 edition will bring together 40+ distinguished speakers, global thought leaders, and over 300 industry stakeholders from biopharma, biotech, academia, and regulatory bodies.